Prolexys Pharmaceuticals Inc. has raised $20 million in a preferred series A1 financing round led and managed by Friedli Corporate Finance AG. The money will be used in part to further advance the company's compound, PRLX 93936, a potential cancer therapy currently in Phase I testing. The study, which has dosed 15 patients so far, is designed to identify a safe dose level for therapeutic treatment. In addition, the financing allows Prolexys to pursue backup molecules that may offer additional advantages beyond PRLX …
No comments:
Post a Comment